Moreover, our previous studies showed that liraglutide inhibited the pancreatic cancer cell growth, migration and invasion through activation of cAMP production and consequent inhibition of the PI3K/Akt and ERK1/2 signaling pathways in a GLP-1 receptor-dependent manner [12,13]. The gene discussed is GLP1R; the disease is pancreatic neoplasm.